2021
RIPK3 Activates MLKL-mediated Necroptosis and Inflammasome Signaling during Streptococcus Infection.
Huang HR, Cho SJ, Harris RM, Yang J, Bermejo S, Sharma L, Dela Cruz CS, Xu JF, Stout-Delgado HW. RIPK3 Activates MLKL-mediated Necroptosis and Inflammasome Signaling during Streptococcus Infection. American Journal Of Respiratory Cell And Molecular Biology 2021, 64: 579-591. PMID: 33625952, PMCID: PMC8086037, DOI: 10.1165/rcmb.2020-0312oc.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnimalsCalcium ChannelsCase-Control StudiesDisease Models, AnimalFemaleGene Expression RegulationHumansInflammasomesMacrophages, AlveolarMaleMiceMice, Inbred C57BLMice, KnockoutMiddle AgedMitochondriaMitochondrial Permeability Transition PoreNecroptosisNLR Family, Pyrin Domain-Containing 3 ProteinPneumonia, PneumococcalProtein KinasesProto-Oncogene Proteins c-aktReactive Oxygen SpeciesReceptor-Interacting Protein Serine-Threonine KinasesSignal TransductionStreptococcus pneumoniaeConceptsCommunity-acquired pneumoniaPneumococcal pneumoniaSevere pathological damageHealthy control subjectsPotential plasma markerNLRP3 inflammasome activationCommon bacterial pathogensMitochondrial permeability transition pore openingStreptococcal pneumoniaPlasma markersStreptococcus infectionBacterial clearanceControl subjectsPathological damageLeading causeMitochondrial reactive oxygenInflammasome activationMurine modelMitochondrial calcium uptakePneumoniaPermeability transition pore openingHuman studiesHigh mortalityInflammasome signalingTransition pore openingCutting Edge: Severe SARS-CoV-2 Infection in Humans Is Defined by a Shift in the Serum Lipidome, Resulting in Dysregulation of Eicosanoid Immune Mediators
Schwarz B, Sharma L, Roberts L, Peng X, Bermejo S, Leighton I, Casanovas-Massana A, Minasyan M, Farhadian S, Ko AI, Team Y, Dela Cruz CS, Bosio CM. Cutting Edge: Severe SARS-CoV-2 Infection in Humans Is Defined by a Shift in the Serum Lipidome, Resulting in Dysregulation of Eicosanoid Immune Mediators. The Journal Of Immunology 2021, 206: ji2001025. PMID: 33277388, PMCID: PMC7962598, DOI: 10.4049/jimmunol.2001025.Peer-Reviewed Original ResearchConceptsLipid mediatorsRisk factorsSevere diseaseSevere SARS-CoV-2 infectionHospitalized COVID-19 patientsSARS-CoV-2 infectionImportant immune regulatory roleSevere COVID-19COVID-19 patientsImmune regulatory roleProinflammatory lipid mediatorsCOVID-19Immunomodulatory eicosanoidsImmune mediatorsSerum lipidomeAdvanced agePatientsCOVID-19 pandemicCytochrome P450MortalityDiseaseDysregulationMediatorsLMS productsLipidome
2020
The kinetics of humoral response and its relationship with the disease severity in COVID-19
Ren L, Zhang L, Chang D, Wang J, Hu Y, Chen H, Guo L, Wu C, Wang C, Wang Y, Wang Y, Wang G, Yang S, Dela Cruz CS, Sharma L, Wang L, Zhang D, Wang J. The kinetics of humoral response and its relationship with the disease severity in COVID-19. Communications Biology 2020, 3: 780. PMID: 33311543, PMCID: PMC7733479, DOI: 10.1038/s42003-020-01526-8.Peer-Reviewed Original ResearchConceptsHumoral responseDisease severityReceptor-binding domainAntibody titersSpike proteinSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2COVID-19Respiratory syndrome coronavirus 2Titers of NAbsGeometric mean titersCOVID-19 patientsSyndrome coronavirus 2Coronavirus disease 2019Disease courseMean titersCoronavirus 2Antibody responseIgG antibodiesRisk factorsIg levelsImmunoglobulin ADisease 2019Severe casesModerate infectionsSevere respiratory viral infection induces procalcitonin in the absence of bacterial pneumonia
Gautam S, Cohen AJ, Stahl Y, Toro P, Young GM, Datta R, Yan X, Ristic NT, Bermejo SD, Sharma L, Restrepo M, Dela Cruz CS. Severe respiratory viral infection induces procalcitonin in the absence of bacterial pneumonia. Thorax 2020, 75: 974-981. PMID: 32826284, DOI: 10.1136/thoraxjnl-2020-214896.Peer-Reviewed Original ResearchConceptsPure viral infectionBacterial coinfectionViral infectionInfluenza infectionSevere respiratory viral infectionsAbility of procalcitoninRetrospective cohort studyViral respiratory infectionsRespiratory viral infectionsMarker of severityRespiratory viral illnessSevere viral infectionsSpecificity of procalcitoninCharacteristic curve analysisCellular modelHigher procalcitoninProcalcitonin expressionElevated procalcitoninCohort studyViral illnessRespiratory infectionsAntibiotic administrationBacterial pneumoniaSevere diseaseProcalcitoninPersistent Viral Presence Determines the Clinical Course of the Disease in COVID-19
Chang D, Zhao P, Zhang D, Dong JH, Xu Z, Yang G, Li BY, Liu HX, Li BA, Qin CF, Peng XH, Wang FS, Xie LX, Chen Z, Dela Cruz CS, Sharma L, Qin EQ. Persistent Viral Presence Determines the Clinical Course of the Disease in COVID-19. The Journal Of Allergy And Clinical Immunology In Practice 2020, 8: 2585-2591.e1. PMID: 32574840, PMCID: PMC7305869, DOI: 10.1016/j.jaip.2020.06.015.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedBetacoronavirusC-Reactive ProteinChildChild, PreschoolComorbidityCoronavirus InfectionsCOVID-19FemaleGlucocorticoidsHumansInfantInflammationInflammation MediatorsInterleukin-6MaleMiddle AgedPandemicsPneumonia, ViralReal-Time Polymerase Chain ReactionRespiration, ArtificialSARS-CoV-2Severity of Illness IndexYoung AdultConceptsDisease severityViral clearanceViral persistenceDisease outcomeCOVID-19Viral presenceExtensive lung involvementC-reactive proteinEffective antiviral therapyCoronavirus disease 2019Severe disease outcomesHost antiviral mechanismsInfectious viral particlesImmunomodulatory therapyInflammatory markersLung involvementRespiratory supportClinical courseAntiviral therapyIL-6Viral reactivationClinical managementInflammatory responseChest imagingDisease 2019Time Kinetics of Viral Clearance and Resolution of Symptoms in Novel Coronavirus Infection
Chang D, Mo G, Yuan X, Tao Y, Peng X, Wang FS, Xie L, Sharma L, Dela Cruz CS, Qin E. Time Kinetics of Viral Clearance and Resolution of Symptoms in Novel Coronavirus Infection. American Journal Of Respiratory And Critical Care Medicine 2020, 201: 1150-1152. PMID: 32200654, PMCID: PMC7193851, DOI: 10.1164/rccm.202003-0524le.Peer-Reviewed Original Research
2017
The microbiome of the lung and its extracellular vesicles in nonsmokers, healthy smokers and COPD patients
Kim HJ, Kim YS, Kim KH, Choi JP, Kim YK, Yun S, Sharma L, Dela Cruz CS, Lee JS, Oh YM, Lee SD, Lee SW. The microbiome of the lung and its extracellular vesicles in nonsmokers, healthy smokers and COPD patients. Experimental & Molecular Medicine 2017, 49: e316-e316. PMID: 28408748, PMCID: PMC5420800, DOI: 10.1038/emm.2017.7.Peer-Reviewed Original ResearchConceptsChronic obstructive pulmonary diseaseCOPD groupLung tissueClinical characteristicsHealthy smokersNormal spirometryPresence of COPDExtracellular vesiclesHealthy smoker groupParticipants' clinical characteristicsSurgical lung tissueObstructive pulmonary diseaseChronic inflammatory diseaseSame mean ageRibosomal RNA gene sequencingRNA gene sequencingCOPD patientsSmoker groupImmune dysfunctionPulmonary diseaseSmoking statusMean ageNanometer-sized extracellular vesiclesLung microbiomeInflammatory diseases